Skip to main content
Premium Trial:

Request an Annual Quote

Galapagos Will Use siRNA Vectors to Help Dutch Partners Develop Tx for Spinal Disorders

NEW YORK, Sept. 14 (GenomeWeb News) - Galapagos will help Amsterdam Molecular Therapeutics, the Netherlands Institute for Brain Research, and the Vrije Universiteit Amsterdam develop treatments for acute spinal cord and peripheral nerve damage, the company said today.


The collaboration, funded in part by a2 million ($2.5 million) grant from the Dutch government organization Senter, aims to develop drugs that promote nerve regeneration and reduce the effect of neural scarring, Galapagos said.


Terms of the deal call for the Dutch company to provide access to its siRNA vectors on a fee-for-service basis. It is hoped that access to this technology will enable the partners to "discover protein targets involved in regeneration of injured nerve tissue."


Once these targets have been identified, Amsterdam Molecular Therapeutics will develop technologies based on their gene therapy platform. The Netherlands Institute for Brain Research, meantime, will use its expertise in neuroregeneration and microarray technology and the Vrije Universiteit Amsterdam will analyze nerve cell growth to further develop the therapeutics, according to Galapagos.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.